Haemoctin Sdh (Human Coagulation Factor Viii)

Haemoctin Sdh is a prescription intravenous concentrate containing human coagulation factor VIII. It is supplied as a sterile solution intended for intravenous administration. The product is marketed in the European Union and is classified as a factor VIII concentrate, a hemostatic agent used to replace deficient factor VIII in patients with hemophilia A. It is provided in a single‑use vial and stored under refrigeration until use.

Haemoctin Sdh is indicated for the management of bleeding episodes and perioperative prophylaxis in individuals with hemophilia A.

- Treatment of acute spontaneous or traumatic bleeds in patients with factor VIII deficiency. - Surgical or dental procedures requiring hemostatic coverage. - Routine prophylaxis to reduce the frequency of bleeding episodes. - On‑demand therapy for breakthrough bleeding while on a prophylactic regimen. - Management of inhibitor development when used in conjunction with immune tolerance induction protocols. - Adjunctive use in patients undergoing major orthopedic surgery to maintain adequate hemostasis.

The safety profile of Haemoctin Sdh reflects the typical observations for factor VIII replacement products, with most patients experiencing mild, transient reactions and a smaller proportion developing more serious complications. Monitoring during and after infusion helps identify and manage these events promptly.

Common: - Mild headache or fatigue. - Low‑grade fever. - Localized infusion site reactions such as redness or swelling. - Transient increase in liver enzymes. - Nausea or mild abdominal discomfort. - Transient arthralgia or joint pain.

Serious: - Development of inhibitors (antibodies) against factor VIII. - Anaphylactic or severe allergic reactions. - Thromboembolic events, including deep vein thrombosis. - Hemolysis or renal impairment. - Disseminated intravascular coagulation (rare).

When prescribing Haemoctin Sdh, clinicians should consider several precautionary measures to ensure safe and effective use in patients with hemophilia A.

- Assess for a history of factor VIII inhibitors before initiating therapy. - Perform baseline screening for viral infections (e.g., HIV, hepatitis B/C) due to plasma‑derived origins. - Monitor for signs of allergic reactions during the first infusion. - Adjust dosing in patients with renal or hepatic impairment as recommended. - Use caution in individuals with a predisposition to thrombosis. - Store the product according to manufacturer guidelines to maintain potency. - Educate patients on proper infusion techniques and emergency signs.

Haemoctin Sdh may interact with other medications or substances that affect coagulation or immune response, requiring careful management.

Avoid: - Concurrent use of other factor VIII concentrates without medical supervision. - Administration of pro‑coagulant agents such as activated prothrombin complex concentrates unless indicated.

Use with caution: - Antifibrinolytic drugs (e.g., tranexamic acid) may increase clot stability and should be coordinated. - Immunosuppressive therapies that could alter inhibitor development. - Vaccines, particularly live attenuated, administered close to infusion times. - Concomitant use of nephrotoxic or hepatotoxic drugs, given potential organ stress. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase bleeding risk and should be reviewed.